Phase 3 N=721 A Study of Fibrocaps™ in Surgical Bleeding
Mild or Moderate Surgical Bleeding
Primary: Time to Hemostasis (TTH) for Participants Receiving Spinal Surgery — 1.0; 2.5 minutes — p=< 0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
HER2-Positive Early Stage Breast Cancer
Primary: Number of Participants Who Are Able to Complete THL (Paclitaxel, Trastuzumab, and Lapatinib) Without a Dose Delay or Reduction, Grade 3 or Greater QTc Prolongation — 16…
N/A N=1,500 Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes
Acute Coronary Syndrome · Depressive Symptoms
Primary: Quality-Adjusted Life Years (QALYs) — -0.06; -0.06; -0.06 quality-adjusted life years (QALYs) — p=0.98
Phase 3 N=30 Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
Type II; Diabetes
Primary: Measurement of the Change in Plasma Glucose (mg/dL): Study 1 — -29; -17 mg/dl
N/A N=6 Psychological Intervention for Caregivers of Patients Undergoing Hematopoietic Stem Cell Transplantation (HCT)
Stem Cell Transplant Complications
Primary: Pilot Qualitative Refinement of the Caregiver Intervention — 5; 5; 3; 5 Participants
Phase 3 N=99 Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)
Acute Myocardial Infarction
Primary: Acute Phase Response (CRP Levels) — 60.03; 86.35; 213.75 mg x day/L (milligram x day/liter)
Phase 2 N=10 Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla
Type 1 Diabetes
Primary: Brain Glycogen Turnover Rate — 0.31; 0.28 mg/kg/min
Phase 3 N=210 Rifaximin for Prevention of Travellers' Diarrhea
Diarrhea
Primary: Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment — 15; 48 Participants
Phase 3 N=122 A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event — 7; 6; 3; 5 Participants
Phase 3 N=398 Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change in Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — 14.9; 13.5 Score on Scale — p=0.0438
N/A N=58 Clinical Study to Evaluate the Correction of Wrinkles and Folds and Safety of YVOIRE Classic Versus Restylane in Nasolabial Fold Intradermal Injection
Temporary Correction of Wrinkles
Primary: Average of Wrinkle Severity Rating Scale (WSRS) Score Evaluated by the Evaluating Investigator at Week 26 (Visit 7) After the Final Treatment With the Investigational…
Phase 2 N=36 A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
Systemic Lupus Erythematosus
Primary: Maximum Concentration of Anifrolumab in Serum After First Dose — 14.058; 28.115 mcg/mL
Phase 3 N=404 Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — 14.7; 11.3 Score on Scale — p=0.0048
Phase 2 N=22 A Trial of Tocilizumab in ALS Subjects
ALS · Amyotrophic Lateral Sclerosis · Lou Gehrig's Disease
Primary: Number of Patients Tolerant to Study Drug — 6; 12 Participants — p=0.602
N/A N=24 New Therapeutical Perspectives in Cases of Phonological Disorders
Speech Sound Disorders
Primary: Percentage of Consonants Correct (PCC) Pre-treatment and Post-treatment Phonological Instrument — 70.63; 68.13; 75.5; 79.88 PCC - (%) — p=0.001